Curt Bradshaw - NeuBase Therapeutics Chief Officer
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
Insider
Curt Bradshaw is Chief Officer of NeuBase Therapeutics
| Age | 59 |
| Phone | 412 763 3350 |
| Web | https://www.neubasetherapeutics.com |
NeuBase Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4303) % which means that it has lost $0.4303 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9346) %, meaning that it created substantial loss on money invested by shareholders. NeuBase Therapeutics' management efficiency ratios could be used to measure how well NeuBase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.NeuBase Therapeutics currently holds 6 M in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. NeuBase Therapeutics has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about NeuBase Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter Moesta | Compass Therapeutics | N/A | |
| Susan Kalled | Compass Therapeutics | 61 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Louise Kooij | NewAmsterdam Pharma | 48 | |
| Inbar GahaliSass | Biomx Inc | N/A | |
| Annie Neild | NewAmsterdam Pharma | N/A | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Inbal BenjaminiElran | Biomx Inc | N/A | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Gabriel BA | Immix Biopharma | 37 | |
| Assaf Oron | Biomx Inc | 50 | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| DSc MSE | Immix Biopharma | 75 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Merav Bassan | Biomx Inc | 58 | |
| JeanPaul MD | Inventiva Sa | N/A | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.93 | |||
| Return On Asset | -0.43 |
NeuBase Therapeutics Leadership Team
Elected by the shareholders, the NeuBase Therapeutics' board of directors comprises two types of representatives: NeuBase Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuBase. The board's role is to monitor NeuBase Therapeutics' management team and ensure that shareholders' interests are well served. NeuBase Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuBase Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Todd Branning, CFO Secretary | ||
| Dietrich Stephan, President CEO, Director | ||
| Curt Bradshaw, Chief Officer | ||
| Robert Zamboni, Chief Board | ||
| Alan JD, G Counsel | ||
| Ron MBA, Sr Devel | ||
| Shannon McCarthy, Chief Officer |
NeuBase Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NeuBase Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.93 | |||
| Return On Asset | -0.43 | |||
| Current Valuation | (5.83 M) | |||
| Shares Outstanding | 3.75 M | |||
| Shares Owned By Insiders | 13.37 % | |||
| Shares Owned By Institutions | 12.68 % | |||
| Number Of Shares Shorted | 15.57 K | |||
| Price To Earning | (4.17) X | |||
| Price To Book | 0.18 X | |||
| EBITDA | (32.49 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |